<DOC>
	<DOC>NCT01315886</DOC>
	<brief_summary>The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer pain (BTcP).</brief_summary>
	<brief_title>Conversion From Fast Acting Oral Opioids to AbstralÂ®</brief_title>
	<detailed_description>The study aims to show that in the advanced stage of cancer the individual patient already on high doses of BTcP medication will benefit from starting treatment on a higher first dose of SL fentanyl thus reducing the number of dosing steps with insufficient pain relief.</detailed_description>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Signed informed consent obtained. 18 years or older, of both genders. Opioid tolerant patients Estimated frequency of BTcP 0.54 times a day. Treatment with SL fentanyl within two weeks prior to screening. Recent or planned therapy that would alter pain or responses to analgesics. Treatment with monoamine oxidase inhibitor &lt; 14 days before or concurrent with SL fentanyl treatment. Significantly reduced liver and/or kidney function. Significant prior history of substance abuse. Pregnancy, breast feeding or woman of childbearing potential not using adequate birth control.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>sublingual</keyword>
	<keyword>fentanyl</keyword>
	<keyword>titration</keyword>
	<keyword>conversion</keyword>
	<keyword>breakthrough cancer pain</keyword>
	<keyword>pain intensity difference</keyword>
	<keyword>PID</keyword>
	<keyword>Edmonton Symptom Assessment System</keyword>
	<keyword>ESAS</keyword>
</DOC>